Gastritis News and Research

RSS

Gastritis is not a single disease, but several different conditions that all have inflammation of the stomach lining. Gastritis can be caused by drinking too much alcohol, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen, or infection with bacteria such as Helicobacter pylori (H. pylori). Sometimes gastritis develops after major surgery, traumatic injury, burns, or severe infections. Certain diseases, such as pernicious anemia, autoimmune disorders, and chronic bile reflux, can cause gastritis as well.

Researchers identify five recurrent fusion genes involved in acute gastritis and cancer

Studying the gastric cancers of 15 Southeast Asian patients, researchers at The Jackson Laboratory, the Genome Institute of Singapore and other institutions identified five recurrent fusion genes, one of which appears to lead to cellular changes involved in acute gastritis and cancer.

10 Jul 2015

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Around half of the global population is chronically infected with the stomach bacterium Helicobacter pylori, almost 1 percent of whom go on to develop gastric adenocarcinoma, one of the deadliest forms of cancer. Usually it takes many decades for the cancer to develop, making it difficult to pinpoint exactly how it is linked to an infection.

17 Jun 2015

CHOP joins CEGIR to advance treatment of eosinophilic disorders

The Children's Hospital of Philadelphia has joined a new consortium announced today by the National Institutes of Health to advance the treatment of chronic inflammatory diseases called eosinophilic disorders.

9 Oct 2014

Pediatric specialist in EGIDs helps lead $6.25 million NIH clinical research project

A pediatric specialist in eosinophilic gastrointestinal diseases (EGIDs) at the University of Colorado School of Medicine and Children's Hospital Colorado will help lead a five-year, $6.25 million clinical research project recently funded by the National Institutes of Health.

9 Oct 2014

Understanding ways to treat, cure eosinophilic gastritis

Investigators at Cincinnati Children's Hospital Medical Center have published the first study to extensively characterize eosinophilic gastritis (EG).

24 Sep 2014

Oxabact now recognized as potential treatment for Short Bowel Syndrome

SBS is a highly disabling malabsorptive condition. SBS is associated with significant morbidity and mortality, reduced quality of life and high healthcare costs.

23 Sep 2014

Wolters Kluwer introduces new editions of 2 definitive guides in pathology

Wolters Kluwer Health, a leading global provider of information and point-of-care solutions for the healthcare industry and students of medicine, has introduced new editions of two definitive guides in pathology.

21 Jul 2014

C-section delivery, early antibiotic treatment linked to eosinophilic esophagitis in children

Children delivered by cesarean section and those given antibiotics during early infancy appear more prone to developing allergic inflammation of the esophagus — the muscular tube that connects the mouth to the stomach — according to results of a study by investigators from the Johns Hopkins Children’s Center and Harvard Medical School.

13 May 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium. It contains the same active moiety (esomeprazole) in a different salt form as found in the leading PPI brand Nexium (esomeprazole magnesium) and presents a potentially more affordable treatment option for GERD in adult patients.

6 Jan 2014

International researchers study glycans that could help clinicians diagnose gastric cancer early

Gastric cancer kills more than 700,000 people each year, mostly in Latin America, Asia and Eastern Europe. Though the disease is quite treatable when caught early, symptoms are indistinct and late detection leads to high mortality. The five-year survival rate in the United States is 26.9 percent.

22 Dec 2013

Researchers develop oral vaccine against Helicobacter pylori

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

20 Dec 2013

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease.

17 Dec 2013

State highlights: Health care price data and transparency in N.Y. and Calif.; states shift tobacco settlement funds away from prevention

Just how expensive is your hospital? In New York, the answer may lie in a trove of hospital cost data newly posted online by the State Health Department. As part of an effort to make health care pricing more transparent, the state is naming hospitals and listing their median charges and costs for 1,400 conditions and procedures from 2009 to 2011.

11 Dec 2013

First Edition: December 10, 2103

Today's early morning highlights from the major news organizations, including reports about how health law advocates are developing new messaging strategies.

10 Dec 2013

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Finnish healthcare company Biohit Oyj and American company Dynex Technologies, Inc. have signed an agreement for the distribution of the two-microplate DS2®, four-microplate DSX® and 12-microplate Agility® automated ELISA (enzyme-linked immunosorbent assay) processing systems, for use with the Biohit Oyj GastroPanel.

4 Dec 2013

Special issue on Helicobacter pylori provides new insights into diagnosis, prevention and treatment

A special issue on Helicobacter pylori has been published by Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Gut Microbes have been authored by world-class investigators and provide new insights into the pathophysiology, diagnosis, prevention, and treatment of this microbe.

20 Nov 2013

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Friends and family members of people with thoracic aortic disease and fans of the late legendary comedic actor John Ritter will come together as Team Ritter to raise funds for the John Ritter Foundation for Aortic Health at the ING New York City Marathon on Nov. 3, 2013.

10 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

New animal model may help study immune responses to H. pylori infection

Researchers at the Virginia Bioinformatics Institute at Virginia Tech have developed a new large animal model to study how the immune system interacts with the stomach bacterium Helicobacter pylori, the leading cause of peptic ulcer disease.

26 Sep 2013